2,3-dimethyl-5,6,7,8-tetrahydro-quinoline | 91245-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,3-dimethyl-5,6,7,8-tetrahydro-quinoline
• 英文别名: 2,3-Dimethyl-5,6,7,8-tetrahydro-chinolin；5,6,7,8-Tetrahydro-dimethylquinoline；2,3-dimethyl-5,6,7,8-tetrahydroquinoline
• CAS: 91245-79-3
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: YQIJPSMCDBTCAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,3-dimethyl-5,6,7,8-tetrahydro-quinoline 在 乙醇 、 sodium 作用下， 生成 2,3-dimethyl-decahydro-quinoline
  参考文献：
  名称：

  v. Braun; Gmelin; Schultheiss, Chemische Berichte, 1923, vol. 56, p. 1343

  摘要：

  DOI：
• 作为产物：
  描述：

  靛红 在 镍 、 萘烷 作用下， 150.0 ℃ 、2.03 MPa 条件下， 生成 2,3-dimethyl-5,6,7,8-tetrahydro-quinoline
  参考文献：
  名称：

  v. Braun; Gmelin; Schultheiss, Chemische Berichte, 1923, vol. 56, p. 1343

  摘要：

  DOI：

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME
  申请人：OHGIYA Tadaaki

  公开号：US20090062306A1

  公开（公告）日：2009-03-05

  A compound represented by the following general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R 6 represents an alkyl group, a cycloalkyl group and the like, R 7 and R 8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R 9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R 10 and R 11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

  通式（I）表示的化合物，其中R1、R2、R3、R4和R5表示氢原子、卤原子、低烷基基团等，R6表示烷基基团、环烷基基团等，R7和R8表示氢原子、低烷基基团、（低环烷基）（低烷基）基团等，R9表示氢原子、卤原子、低烷氧基团等，R10和R11表示氢原子、低烷基基团、低烷氧基团、卤代（低烷基）基团等，A表示由6到10个原子构成的杂环环，对胆固醇酯转移蛋白（CETP）具有强大的抑制活性。
• Chemokine Receptor Antagonist and Medical Use Thereof
  申请人：Habashita Hiromu

  公开号：US20070254886A1

  公开（公告）日：2007-11-01

  The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.

  本发明涉及一种由公式（I）表示的化合物，其盐、N-氧化物、溶剂化物或前药，以及其医药用途（公式中的符号如说明书所述）。公式（I）表示的化合物具有趋化因子受体（尤其是在CCR4和/或CCR5中）拮抗活性。因此，它对于预防和/或治疗趋化因子受体介导的疾病，如炎症和/或过敏性疾病[全身性炎症反应综合征（SIRS）、过敏性休克、过敏性反应、过敏性血管炎、移植排斥反应、肝炎、肾炎、肾病、胰腺炎、鼻炎、关节炎、炎症性眼部疾病、炎症性肠病、脑和/或循环系统疾病、呼吸系统疾病、皮肤病、自身免疫性疾病等]、感染[病毒性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合征、SARS等）等]等非常有用。
• Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
  申请人：Baruah Anima

  公开号：US20070015758A1

  公开（公告）日：2007-01-18

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了新的苄基胺化合物，包括苄基胺化合物的组合物，制备苄基胺化合物的方法，以及使用苄基胺化合物治疗或预防与脂蛋白代谢有关的各种疾病或症状的方法。
• SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20150216866A1

  公开（公告）日：2015-08-06

  The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.

  本发明提供了一种治疗或预防与脂蛋白代谢有关的人类或动物主体的疾病或状况的方法，该方法包括向该主体给予含有苄胺化合物的组合物。